drug

Conflict-of-interest training reduces brand-name antidepressant prescription

Saturday, February 09, 2013 by: David Gutierrez, staff writer
Tags: brand name drugs, antidepressants, conflicts of interest

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
BACK INTO THE CLOSET: Why U.S. reporters are not allowed to write about rainbow events in nations where being gay is still condemned
Depopulation test run? 75% of children who received vaccines in Mexican town now dead or hospitalized
INVESTIGATION: Three days before Dr. Bradstreet was found dead in a river, U.S. govt. agents raided his research facility to seize a breakthrough cancer treatment called GcMAF
A family destroyed: Six-month-old dies after clinic injects baby with 13 vaccines at once without mother's informed consent
Biologist explains how marijuana causes tumor cells to commit suicide
BOMBSHELL: China and America already at war: Tianjin explosion carried out by Pentagon space weapon in retaliation for Yuan currency devaluation... Military helicopters now patrolling Beijing
Companies begin planting microchips under employees' skin
BAM! Chipotle goes 100% non-GMO; flatly rejecting the biotech industry and its toxic food ingredients
ECONOMIC SLAVERY FOR ALL: While we were distracted with the Confederate flag flap, Congress quietly forfeited our entire economic future via fast-track trade authority
McDonald's in global profit free fall as people everywhere increasingly reject chemically-altered toxic fast food
March Against Monsanto explodes globally... World citizens stage massive protests across 38 countries, 428 cities... mainstream media pretends it never happened
SCOTUS same-sex marriage decision may have just legalized the concealed carry of loaded firearms across all 50 states, nullifying gun laws everywhere
Vicious attack on Dr. Oz actually waged by biotech mafia; plot to destroy Oz launched after episode on glyphosate toxicity went viral
Nearly every mass shooting in the last 20 years shares one surprising thing? and it's not guns
Holistic cancer treatment pioneer Dr. Nicholas Gonzalez dies suddenly; patients mourn the loss of a compassionate, innovative doctor who helped thousands heal from cancer
Inuit Elders tell NASA Earth Axis Shifted
Wild eyes and bowl cuts: Why do mass shooters always share the same hair styles and crazed zombie stares?
Genetically white woman now claims self-identify as black: If you can choose your gender, can you also choose your race? What about your species? Can a human claim to be a llama?
Delicious
(NaturalNews) Doctors who underwent residencies at institutions with conflict-of-interest policies are significantly less likely to prescribe brand name drugs over generics than doctors who underwent residencies at institutions without such policies, according to a study conducted by researchers from the University of Pennsylvania, Yale School of Public Health, Harvard Medical School and Johns Hopkins Bloomberg School of Public Health.

Health professionals and policymakers have expressed growing concern in recent years over the potential for conflicts of interest in relationships between health providers and pharmaceutical or medical device companies. One specific concern was that the gifts the drug companies provide to physicians and physicians in training, including meals and drug samples, could unduly influence those doctors to prescribe those companies' brand-name products even when generic or other lower-cost alternatives exist.

Such concerns spurred a number of institutions to adopt conflict-of-interest policies; Penn Medicine, for example, adopted one in 2006. The Association of American Medical Colleges adopted a broad conflict-of-interest policy in 2008.

The researchers analyzed the prescriptions written in 2009 by 1,652 psychiatrists who had participated in 162 different residency programs; data was obtained from IMS Health. Approximately half of the psychiatrists in the sample had completed their residencies in 2001, when there were nearly no conflict-of-interest policies in place, while the other half had completed their residencies in 2008, after widespread adoption of such policies. The researchers further ranked the psychiatrists based on the strictness of the policies at the institutions they had attended.

"Our study focuses on antidepressants because they have been among the most heavily marketed drug classes," said first author Andrew J. Epstein. "Data show that antidepressant use increased nearly 400 percent from 1988 to 2008. The goal for this study was to determine whether exposure to COI policies during residency would influence psychiatrists' antidepressant prescribing patterns after graduation."

Brand name antidepressants, like drugs from many other classes, are heavily promoted to both consumers and medical professionals. One concern with over-prescription of brand name drugs is that such a practice drives up medical costs for both patients and for public healthcare agencies, such as Medicare.

Policies yield concrete results

Because brand name antidepressants are more expensive, the researchers predicted that psychiatrists with fewer conflicts of interest with drug companies would be more likely to prescribe less expensive, generic drugs. And indeed, the researchers found that psychiatrists who had completed their residency in 2008 prescribed brand name antidepressants at significantly lower rates than those who had finished in 2001. Graduates of 2008 programs with the strictest conflict-of-interest policies had the lowest rates of brand name antidepressant prescription.

The study is the first to provide empirical evidence that conflict-of-interest policies have a real effect on the future prescribing behaviors of medical residents. Epstein noted that further research is now needed to see if the same results can be seen with doctors in different specialties and in different classes of drugs.

"Our study clearly shows that implementation of [conflict-of-interest] policies have helped shield physicians from the often persuasive aspects of pharmaceutical promotion," Epstein said.

Sources:

http://www.sciencedaily.com/releases/2013/01/130118104123.htm

Follow real-time breaking news headlines on
Brand name drugs at FETCH.news
Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.